11 Stocks That Will Bounce Back According to Analysts

Page 9 of 10

2. Immunovant, Inc. (NASDAQ:IMVT)

Year-to-Date Performance: -39.58%

Average Price Target Upside Potential According to Analysts: 228.52%

Number of Hedge Fund Holders: 35

Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage immunology company that is focused on developing therapies for patients with autoimmune diseases. The company is a leader in anti-FcRn technology and develops innovative and targeted treatments to meet the complex needs of people with autoimmune diseases. Immunovant, Inc. (NASDAQ:IMVT) ranks among stocks that will bounce back according to analysts.

The company is focused on moving rapidly to unlock the full potential of IMVT-1402, its lead asset. IMVT-1402 is designed to be a leading anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases. Immunovant, Inc. (NASDAQ:IMVT) aims to initiate clinical trials evaluating IMVT-1402 in ten indications by March 31, 2026. So far, the company has reported six Investigational New Drug (IND) applications have been cleared. Immunovant, Inc. (NASDAQ:IMVT) is also running pivotal studies in Graves’ disease and difficult-to-treat rheumatoid arthritis. Additionally, the company is expecting results from another drug, batoclimab, for Graves’ disease. This will include data on patients who would stay in remission for 6 months without treatment, which is expected in summer 2025.

Page 9 of 10